Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jul;40(7):1676–1681. doi: 10.1128/aac.40.7.1676

Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus.

R J Wallace Jr 1, A Meier 1, B A Brown 1, Y Zhang 1, P Sander 1, G O Onyi 1, E C Böttger 1
PMCID: PMC163394  PMID: 8807061

Abstract

Resistance to clarithromycin among isolates of Mycobacterium chelonae and M. abscessus was observed in 18 of 800 (2.3%) patients tested between 1990 and 1995. Patients whose isolates were resistant had either disseminated disease or chronic lung disease, and the resistant isolates were recovered after clarithromycin monotherapy. Sequencing of the gene coding for the 23S rRNA peptidyltransferase region revealed a point mutation involving adenine at position 2058 (38%) or adenine at position 2059 (62%) in 20 of 20 relapse isolates from the first 13 patients identified. By pulsed-field gel electrophoresis or random amplified polymorphic DNA PCR, initial and relapse isolates were shown to have identical DNA patterns. M. chelonae and M. abscessus isolates were found to have only a single chromosomal copy of the rRNA operon, thus making them susceptible to single-step mutations. Thus, clarithromycin resistance in these species of rapidly growing mycobacteria relates to a point mutation in the gene coding for 23S rRNA and occurs in limited clinical situations, but was identified in almost 5% of isolates tested in 1995.

Full Text

The Full Text of this article is available as a PDF (373.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bercovier H., Kafri O., Sela S. Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome. Biochem Biophys Res Commun. 1986 May 14;136(3):1136–1141. doi: 10.1016/0006-291x(86)90452-3. [DOI] [PubMed] [Google Scholar]
  2. Berman S. M., Kim R. C., Haghighat D., Mulligan M. E., Fierer J., Wyle F. C. Mycobacterium genavense infection presenting as a solitary brain mass in a patient with AIDS: case report and review. Clin Infect Dis. 1994 Dec;19(6):1152–1154. doi: 10.1093/clinids/19.6.1152. [DOI] [PubMed] [Google Scholar]
  3. Brown B. A., Wallace R. J., Jr, Onyi G. O. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother. 1992 Sep;36(9):1987–1990. doi: 10.1128/aac.36.9.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brown B. A., Wallace R. J., Jr, Onyi G. O., De Rosas V., Wallace R. J., 3rd Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother. 1992 Jan;36(1):180–184. doi: 10.1128/aac.36.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown B. A., Wallace R. J., Jr, Onyi G. Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria. Antimicrob Agents Chemother. 1996 Apr;40(4):874–878. doi: 10.1128/aac.40.4.874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chaisson R. E., Benson C. A., Dube M. P., Heifets L. B., Korvick J. A., Elkin S., Smith T., Craft J. C., Sattler F. R. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994 Dec 15;121(12):905–911. doi: 10.7326/0003-4819-121-12-199412150-00001. [DOI] [PubMed] [Google Scholar]
  7. Dautzenberg B., Piperno D., Diot P., Truffot-Pernot C., Chauvin J. P. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest. 1995 Apr;107(4):1035–1040. doi: 10.1378/chest.107.4.1035. [DOI] [PubMed] [Google Scholar]
  8. Dautzenberg B., Saint Marc T., Meyohas M. C., Eliaszewitch M., Haniez F., Rogues A. M., De Wit S., Cotte L., Chauvin J. P., Grosset J. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1993 Feb 8;153(3):368–372. [PubMed] [Google Scholar]
  9. Dautzenberg B., Truffot C., Legris S., Meyohas M. C., Berlie H. C., Mercat A., Chevret S., Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):564–569. doi: 10.1164/ajrccm/144.3_Pt_1.564. [DOI] [PubMed] [Google Scholar]
  10. Domenech P., Menendez M. C., Garcia M. J. Restriction fragment length polymorphisms of 16S rRNA genes in the differentiation of fast-growing mycobacterial species. FEMS Microbiol Lett. 1994 Feb 1;116(1):19–24. doi: 10.1111/j.1574-6968.1994.tb06669.x. [DOI] [PubMed] [Google Scholar]
  11. Heifets L., Mor N., Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother. 1993 Nov;37(11):2364–2370. doi: 10.1128/aac.37.11.2364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jacobs I. N., Potsic W. P. Glomus tympanicum in infancy. Arch Otolaryngol Head Neck Surg. 1994 Feb;120(2):203–205. doi: 10.1001/archotol.1994.01880260073013. [DOI] [PubMed] [Google Scholar]
  13. Kauppinen J., Mäntyjärvi R., Katila M. L. Random amplified polymorphic DNA genotyping of Mycobacterium malmoense. J Clin Microbiol. 1994 Jul;32(7):1827–1829. doi: 10.1128/jcm.32.7.1827-1829.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kiehn T. E., White M. Mycobacterium haemophilum: an emerging pathogen. Eur J Clin Microbiol Infect Dis. 1994 Nov;13(11):925–931. doi: 10.1007/BF02111493. [DOI] [PubMed] [Google Scholar]
  15. Mazurek G. H., Hartman S., Zhang Y., Brown B. A., Hector J. S., Murphy D., Wallace R. J., Jr Large DNA restriction fragment polymorphism in the Mycobacterium avium-M. intracellulare complex: a potential epidemiologic tool. J Clin Microbiol. 1993 Feb;31(2):390–394. doi: 10.1128/jcm.31.2.390-394.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Meier A., Kirschner P., Springer B., Steingrube V. A., Brown B. A., Wallace R. J., Jr, Böttger E. C. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother. 1994 Feb;38(2):381–384. doi: 10.1128/aac.38.2.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nadal D., Caduff R., Kraft R., Salfinger M., Bodmer T., Kirschner P., Böttger E. C., Schaad U. B. Invasive infection with Mycobacterium genavense in three children with the acquired immunodeficiency syndrome. Eur J Clin Microbiol Infect Dis. 1993 Jan;12(1):37–43. doi: 10.1007/BF01997055. [DOI] [PubMed] [Google Scholar]
  18. Nash K. A., Inderlied C. B. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother. 1995 Dec;39(12):2625–2630. doi: 10.1128/aac.39.12.2625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pang Y., Brown B. A., Steingrube V. A., Wallace R. J., Jr, Roberts M. C. Tetracycline resistance determinants in Mycobacterium and Streptomyces species. Antimicrob Agents Chemother. 1994 Jun;38(6):1408–1412. doi: 10.1128/aac.38.6.1408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pernodet J. L., Boccard F., Alegre M. T., Blondelet-Rouault M. H., Guérineau M. Resistance to macrolides, lincosamides and streptogramin type B antibiotics due to a mutation in an rRNA operon of Streptomyces ambofaciens. EMBO J. 1988 Jan;7(1):277–282. doi: 10.1002/j.1460-2075.1988.tb02810.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Silcox V. A., Good R. C., Floyd M. M. Identification of clinically significant Mycobacterium fortuitum complex isolates. J Clin Microbiol. 1981 Dec;14(6):686–691. doi: 10.1128/jcm.14.6.686-691.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Steingrube V. A., Wallace R. J., Jr, Steele L. C., Pang Y. J. Mercuric reductase activity and evidence of broad-spectrum mercury resistance among clinical isolates of rapidly growing mycobacteria. Antimicrob Agents Chemother. 1991 May;35(5):819–823. doi: 10.1128/aac.35.5.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Swenson J. M., Wallace R. J., Jr, Silcox V. A., Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985 Dec;28(6):807–811. doi: 10.1128/aac.28.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Swetter S. M., Kindel S. E., Smoller B. R. Cutaneous nodules of Mycobacterium chelonae in an immunosuppressed patient with preexisting pulmonary colonization. J Am Acad Dermatol. 1993 Feb;28(2 Pt 2):352–355. doi: 10.1016/0190-9622(93)70053-v. [DOI] [PubMed] [Google Scholar]
  25. Tebas P., Sultan F., Wallace R. J., Jr, Fraser V. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis. 1995 Feb;20(2):443–444. doi: 10.1093/clinids/20.2.443. [DOI] [PubMed] [Google Scholar]
  26. Versalovic J., Shortridge D., Kibler K., Griffy M. V., Beyer J., Flamm R. K., Tanaka S. K., Graham D. Y., Go M. F. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother. 1996 Feb;40(2):477–480. doi: 10.1128/aac.40.2.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wallace R. J., Jr, Brown B. A., Griffith D. E., Girard W. M., Murphy D. T., Onyi G. O., Steingrube V. A., Mazurek G. H. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994 May;149(5):1335–1341. doi: 10.1164/ajrccm.149.5.8173775. [DOI] [PubMed] [Google Scholar]
  28. Wallace R. J., Jr, Hull S. I., Bobey D. G., Price K. E., Swenson J. M., Steele L. C., Christensen L. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays. Am Rev Respir Dis. 1985 Aug;132(2):409–416. doi: 10.1164/arrd.1985.132.2.409. [DOI] [PubMed] [Google Scholar]
  29. Wallace R. J., Jr, Swenson J. M., Silcox V. A., Good R. C., Tschen J. A., Stone M. S. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis. 1983 Jul-Aug;5(4):657–679. doi: 10.1093/clinids/5.4.657. [DOI] [PubMed] [Google Scholar]
  30. Wallace R. J., Jr, Tanner D., Brennan P. J., Brown B. A. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med. 1993 Sep 15;119(6):482–486. doi: 10.7326/0003-4819-119-6-199309150-00006. [DOI] [PubMed] [Google Scholar]
  31. Wallace R. J., Jr, Zhang Y., Brown B. A., Fraser V., Mazurek G. H., Maloney S. DNA large restriction fragment patterns of sporadic and epidemic nosocomial strains of Mycobacterium chelonae and Mycobacterium abscessus. J Clin Microbiol. 1993 Oct;31(10):2697–2701. doi: 10.1128/jcm.31.10.2697-2701.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Young L. S., Wiviott L., Wu M., Kolonoski P., Bolan R., Inderlied C. B. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet. 1991 Nov 2;338(8775):1107–1109. doi: 10.1016/0140-6736(91)91965-w. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES